Twist促进乳腺癌细胞BT-549乳腺细胞小球形成及其迁移

目的探讨Twist基因功能缺失对乳腺肿瘤干细胞样细胞富集及其迁移的影响。方法采用shRNA干扰技术构建Twist基因敲减的BT-549乳腺癌细胞株(BT-549-sh Twist细胞株)和阴性对照细胞株BT-549-sh Vec;采用实时荧光定量PCR和Western blot法验证干扰效率;长程无血清悬浮培养方法富集具有干细胞特性的乳腺癌细胞小球(mammosphere);TranswellTM法检测乳腺癌细胞小球的迁移能力。结果采用shRNA干扰技术成功构建Twist基因敲减的BT-549乳腺癌细胞株BT-549-sh Twist细胞株;BT-549-sh Twist细胞株的mammosphere富集能力和迁移能力减弱。结论 Twist促进BT-549乳腺癌乳腺细胞小球形成及其迁移。     

lncRNA VIM-AS5在人乳腺癌细胞系中的表达及对乳腺癌细胞增殖和迁移的影响

目的 探讨长链非编码RNA (lncRNA)VIM-AS5在人乳腺癌组织中表达的临床意义及其对乳腺癌细胞增殖和迁移的作用机制。方法 利用Lnc2Cancer 3.0数据库分析VIM-AS5在乳腺癌组织中的表达及其与乳腺癌患者临床分期、生存期的相关性。RT-qPCR检测乳腺癌BT-549、MDA-MB-435、MDA-MB-231、CAL-51细胞中VIM-AS5的表达量。通过脂质体分别将VIM-AS5过表达质粒和阴性对照质粒转染至CAL-51细胞,依次记为VIM-AS5组和NC组。采用集落形成实验、划痕愈合法分别检测CAL-51细胞的增殖活力和迁移率。双荧光素酶报告基因实验验证VIM-AS5与miR-500a的靶向关系。RT-qPCR检测CAL-51细胞中miR-500a表达。Western blot检测CAL-51细胞中JAK/STAT3分子通路蛋白表达。结果 乳腺癌组织中VIM-AS5表达显著低于癌旁组织(P<0.01)。VIM-AS5表达量与乳腺癌患者的临床分期呈负相关(P<0.01)。VIM-AS5低表达乳腺癌患者的生存期明显短于VIM-AS5高表达乳腺癌患者(P&...     

miR-141-3p通过靶向PDCD1抑制人胃癌细胞系AGS的迁移与侵袭

目的 探讨miR-141-3p对胃癌(GC)细胞迁移与侵袭的影响,并揭示其潜在的分子机制.方法 用RT-qPCR分别检测临床组织样本、正常胃黏膜上皮细胞系GES-1和胃癌细胞系AGS中miR-141-3p的表达.在AGS细胞中转染miR-141-3p mimic后,用Transwell小室法检测细胞的迁移和侵袭;荧光素...     

利用SmartFlare技术进行胶质瘤细胞系U87中Twist1hi亚群分选及其对顺铂耐药性研究

目的 利用特异性SmartFlareTM RNA检测探针在人脑胶质瘤细胞系U87中分选Twist1hi-U87细胞亚群,并研究其对顺铂的耐药性.方法 用SmartFlareTM RNA探针对Twist 1hi-U87细胞亚群进行分选.以未分选细胞作为对照.CCK8法检测Twist1hi-U87亚群和亲代U87细胞对顺铂的化疗敏感性.流式细胞仪检测顺铂作用后细胞凋亡情况.结果 根据细胞核内Twist1的表达量,流式细胞分选所得Twist1hi-U87亚群约占亲代U87细胞的57.9％～ 69.8％.CCK8结果显示,加药后24h和48h,Twist1hi-U87亚群对顺铂的耐药性均高于亲代U87细胞(P＜0.05).经顺铂处理后,Twist1hi-U87细胞凋亡率(14.07％±0.96％)明显低于U87细胞(20.4％±1.29％)(P＜0.05).结论 Twist1基因高表达可以抑制胶质瘤细胞凋亡,进而降低顺铂的杀伤作用.     

Twist对TNF-α作用后乳腺癌细胞侵袭及上皮间质转化的影响

RNA干扰技术抑制Twist在乳腺癌细胞MDA-MB-231中的表达,观察其沉默对TNF-α作用后乳腺癌细胞侵袭及上皮间质转化(epithelial mesenchymal transition,EMT)的影响。以乳腺癌细胞MDA-MB-231为空白对照,shRNA-NC空载体为阴性对照,构建Twist沉默表达载体,转染乳腺癌细胞MDA-MB-231,qRT-PCR和Western blotting检测转染细胞中Twist mRNA及蛋白质表达水平。建立Twist沉默表达的乳腺癌细胞模型后,用TNF-α分别处理对照组及转染后的乳腺癌细胞,Transwell实验检测细胞侵袭和迁移能力,Western blotting检测细胞EMT相关蛋白波形蛋白(Vimentin)、上皮钙黏附素(E-cadherin)和转移相关蛋白基质金属蛋白酶2(matrix metalloproteinase 2, MMP-2)、基质金属蛋白酶9(MMP-9)的表达。结果显示,下调Twist的乳腺癌细胞经TNF-α处理后,细胞侵袭和迁移能力降低,Vimentin表达减少,E-cadherin表达增加,细胞中MMP-2、MMP-9表达减少,与空白对照及TNF-α作用后的阴性对照相比,差异有统计学意义(P0.05)。因此,下调Twist可降低TNF-α诱导的乳腺癌细胞的侵袭和迁移能力,抑制其EMT。     

miR-211通过靶向调控TFAM抑制人乳腺癌细胞系增殖

目的探讨miR-211靶向线粒体转录因子A(TFAM)对人乳腺癌细胞增殖的影响。方法用miR-211及TFAM作为研究对象。首先,在乳腺癌细胞中转染miR-211 mimics或miR-211抑制剂以实现miR-211过表达或miR-211沉默,并检测miR-211过表达或沉默时TFAM蛋白质的表达水平;其次,构建了在TFAM的5'端有或无6对碱基突变的荧光酶报告基因质粒(mut-TFAM/wt-TFAM),与miR-211 mimics或miR-211抑制剂共转染后检测荧光酶活性变化;然后,构建pc DNA3.1/TFAM质粒,与miR-211 mimics或miR-211抑制剂共转染后检测TFAM蛋白质表达水平变化;最后,检测pc DNA3.1/TFAM和mimics NC/miR-211 mimics共转染后乳腺癌细胞增殖的增殖。结果miR-211过表达抑制TFAM蛋白质表达(P0.01),miR-211沉默促进TFAM蛋白质表达(P0.01);miR-211可靶向结合TFAM调控其表达;pc DNA3.1/TFAM可实现TFAM过表达(mRNA P0.01,蛋白质P0.01),并可恢复miR-211对TFAM的抑制作用;miR-211可抑制乳腺癌细胞的增殖和增殖(P0.05),TFAM可促进乳腺癌细胞增殖增殖(P0.01),TFAM可回复miR-211对乳腺癌细胞增殖增殖的抑制作用(P0.05)。结论 miR-211靶向TFAM基因抑制人乳腺癌细胞的增殖。     

KCNK15-AS1靶向miR-21对肺鳞癌恶性生物学行为的影响

目的 探讨KCNK15-AS1靶向miR-21对肺鳞癌细胞迁移和凋亡的影响.方法 选择湘南学院附属医院2018年6月至2019年12月收治的21例肺鳞癌患者的癌组织及癌旁正常组织.采用lncRNA芯片筛选肺鳞癌中差异表达的lncRNA;用实时荧光定量聚合酶链式反应(qRT-PCR)检测用于分析KCNK15-AS1和mi...     

LncRNA SLC16A1-AS1靶向调控miR-182对乳腺癌BT549细胞增殖能力的影响

目的 探讨LncRNA SLC16A1-AS1对miR-182的靶向调控作用及对乳腺癌BT549细胞增殖能力的影响。方法 使用GEPIA2工具分析TCGA数据库中LncRNA SLC16A1-AS1在三阴型乳腺癌(triple negative breast cancer, TNBC)中的差异性表达,应用Kaplan-Meier Plotter数据库进行生存分析。利用RegRNA2和miRanda数据库预测LncRNA SLC16A1-AS1的潜在靶标miRNAs。用qRT-PCR检测LncRNA SLC16A1-AS1在TNBC组织及细胞系(BT549、BT20、MDA-MB-231及MDA-MB-468)中的表达。利用双荧光素酶活性测定及RNA免疫沉淀实验验证LncRNA SLC16A1-AS1与miR-182的结合力。用CCK-8及集落形成实验检测不同处理组BT549细胞增殖能力的变化。结果 生物信息学分析结果显示,TNBC组织中LncRNA SLC16A1-AS1的表达水平显著低于正常组织(P<0.001),与预后良好相关(P<0.001),LncRNA SLC16...     

下调赖氨酰氧化酶样蛋白1(LOXL1)表达抑制乳腺癌细胞的增殖与迁移

目的 探究赖氨酰氧化酶样蛋白1(LOXL1)基因对乳腺癌细胞的增殖及迁移能力的影响。方法 利用基因表达谱交互分析(GEPIA)与Kaplan-Meier分析确定乳腺癌组织LOXL1的表达以及与乳腺癌患者预后的关系。通过慢病毒稳定转染技术,稳定敲低MDA-MB-231细胞和MCF7细胞的LOXL1。采用集落形成实验、 CCK-8法、 5-乙炔基-2′脱氧尿嘧啶核苷(EdU)染色实验检测敲低LOXL1对乳腺癌细胞增殖能力的影响,划痕实验以及Transwell^TM实验检测敲低LOXL1对乳腺癌细胞迁移能力的影响。结果 与正常组织相比,LOXL1在乳腺癌组织高表达,且与不良预后相关;敲低MDA-MB-231、 MCF7乳腺癌细胞LOXL1后,细胞增殖和迁移能力明显降低。结论 敲低LOXL1降低乳腺癌细胞的增殖及迁移能力。     

MiR-146a调节TRAIL不敏感的乳腺癌细胞迁移及其分子机制

目的 研究miR-146a及其靶基因EGFR对乳腺癌细胞迁移的影响.方法 用终浓度为50、100、200和500 μg/L的重组可溶性TRAIL(rsTRAIL)持续刺激对TRAIL敏感的MDA-MB-231细胞4周,筛选得到TRAIL不敏感的乳腺癌细胞MDA-MB-231/TR.RT-PCR检测miR-146a的表达;Transwell实验以及划痕实验检测乳腺癌细胞的迁移能力;双荧光素酶报告基因分析以及Western blot鉴定MDA-MB-231/TR细胞中miR-146a与EGFR基因的靶向调控关系;Western blot检测DR4、DR5、IRAK1、CXCR4、p-IκBα、IκBα、caspase 8和caspase 3的蛋白表达水平;染色质免疫共沉淀技术(ChIP)分析MDA-MB-231和MDA-MB-231/TR细胞中NF-κB P65亚基与miR-146a启动子区的结合情况.结果 TRAIL细胞毒作用不敏感的人乳腺癌细胞系MDA-MB-231/TR中miR-146a的表达降低,并引起其靶基因EGFR的表达增加,最终导致TRAIL不敏感的乳腺癌细胞迁移能力增强.同时发现NF-κB参与miR-146a低表达的调控.结论 miR-146a对TRAIL不敏感的乳腺癌细胞迁移起重要的调节作用.     

Sirtuin SIRT6 suppresses cell proliferation through inhibition of Twist1 expression in non-small cell lung cancer

SIRT6 is a member of the NAD⁺-dependent class III deacetylase sirtuin family. Current studies have revealed that SIRT6 plays important roles in the epigenetic regulation of genes expression and contribute to the proliferation, differentiation and apoptosis of cancer cells. However, the biological function of SIRT6 in lung cancer has not been elucidated. The present study showed that the mRNA and protein levels of SIRT6 were decreased in human non-small cell lung cancer (NSCLC) tissues and cell lines. MTT assay showed that overexpression of SIRT6 could inhibit the proliferation in NSCLC cells. In contrast, SIRT6 knockdown using small interfering RNA promoted NSCLC cells proliferation. On the molecular level, we found that SIRT6 inhibited the expression of Twist1 both at the mRNA and protein levels in NSCLC cells. Taken together, these results demonstrated for the first time that SIRT6 suppressed NSCLC cells proliferation via down-regulation of Twist1 expression and might provide novel therapeutic targets in the treatment of lung cancer.     

MiR-1228 promotes breast cancer cell growth and metastasis through targeting SCAI protein

Breast cancer is the most common cancer in women around the world. However, the molecular mechanisms underlying breast cancer pathogenesis are only partially understood. Here, in this study, we found that miR-1228 was up-regulated in breast cancer cell lines and tissues. Ectopic expression of miR-1228 mimics leads to promoted cell growth, invasion and migration. Using bioinfomatic analysis and 3’UTR luciferase reporter assay, we determined SCAI can be directly targeted by miR-1228, which can down-regulate endogenous SCAI protein level. Furthermore, our findings demonstrate that SCAI was down-regulated in breast cancer cell lines and tissues. Rescue experiment demonstrated that miR-1228 promoted cell growth is attenuated by over-expression of MOAP1 and miR-1228 promoted cell invasion and migration can be attenuated by over-expression of SCAI. Taken together, this study provides evidences that miR-1228 serves as an oncogene to promote breast cancer proliferation, invasion and migration, which may become a critical therapeutic target for breast cancer treatment.     

miR-185 acts as a tumor suppressor by targeting AKT1 in non-small cell lung cancer cells

Increasing evidence has shown that microRNAs play critical roles in the initiation and progression of non-small cell lung cancer (NSCLC). miR-185 is deregulated in various cancers, whereas its functional mechanism in NSCLC is still unclear. Here, we confirmed that the expression of miR-185 was significantly down-regulated in NSCLC tissues and cell lines. miR-185 over-expression caused significant suppression of in vitro cell proliferation, migration and invasion, and in vivo tumor growth. We subsequently identified that AKT1 was a target gene of miR-185. Re-expression of AKT1 could partially rescue the inhibitory effects of miR-185 on the capacity of NSCLC cell proliferation and motility. Collectively, we conclude that miR-185 has a critical function by blocking AKT1 in NSCLC cells, and it may be a novel therapeutic agent for miRNA based NSCLC therapy.     

Long noncoding RNA LINC00473 functions as a competing endogenous RNA to regulate MAPK1 expression by sponging miR-198 in breast cancer

Breast cancer (BC) is one of the primary tumors with high incidence in women. The purpose of this study was to investigate the role of LINC00473 and underlying mechanisms in BC. Expression pattern of LINC00473 was analyzed using qRT-PCR (quantitative real-time polymerase chain reaction) assays in BC tissues and cells. Overexpression or knockdown of LINC00473 in vitro and functional experiments were performed to study its effects on BC cells. Target prediction, luciferase assays, RNA fluorescence in situ hybridization and RNA immunoprecipitation were used to verify the role of LINC00473 as a competing endogenous RNA. The impact of LINC00473 on tumor growth was also evaluated using a xenograft model. In our study, we found that LINC00473 was highly expressed in BC tissues and cells, and the elevated expression was correlated with shorter overall survival in patients with BC. Furthermore, knockdown of LINC00473 significantly inhibited the capacity of proliferation, invasion and migration of BC cells. Animal experiment suggested that silencing LINC00473 could significantly inhibit the tumor growth. Following experiments revealed that LINC00473 may function as a competing endogenous RNA to regulate the expression of Mitogen-Activated Protein Kinase 1 (MAPK1) through competition for miR-198. Thus, increased expression of LINC00473 in breast cancer tissues is linked to poor prognosis. LINC00473 may function as an endogenous completive RNA by sponging miR-198 to regulate MAPK1 expression. Findings of our study contributed to the basis for further exploring the application of LINC00473 as a prognostic and diagnostic biomarker.     

miR-760对胃癌细胞系MGC-803增殖、迁移和侵袭的影响

目的探讨miR-760对胃癌细胞系MGC-803增殖、迁移和侵袭的影响。方法 Real-time PCR分析50例胃癌组织(C)及其癌旁(N)中miR-760的表达水平;用pc DNA3.1载体构建过表达miR-760的重组质粒(pc DNA-miR-760),实现miR-760在MGC-803细胞中的过表达;分别用CCK-8法、Transwell和划痕实验检测细胞增殖、侵袭和迁移能力。结果与癌旁对照组相比,36例(72%)胃癌组织中出现miR-760的表达下调;过表达miR-760能显著抑制MGC-803细胞的迁移和侵袭能力(P0.05),但对其增殖影响不大。结论 miR-760的表达下调可能与胃癌的进展有关,过表达miR-760可以抑制胃癌MGC-803细胞的迁移和侵袭。     

miR-593-5p inhibit cell proliferation by targeting PLK1 in non small cell lung cancer cells

Worldwide, lung cancer has the highest rates of mortality and morbidity, with the majority of its pathology attributable to non-small cell lung cancer (NSCLC). MicroRNAs are pivotal in the occurrence and development of cancer. However, the role of miRNA-593-5p in the progression of NSCLC is not clear. In this study, we investigate, in vitro, whether miRNA-593-5p inhibits NSCLC cell proliferation. To clarify its specific mechanism of inhibition, we used bioinformatics to predict its target genes and identified PLK1. Luciferase reporter assay confirmed the binding of miR-593-5p to the PLK1 3′-UTR in a sequence-specific manner in NSCLC cells. Additionally, we also found through Western blot and quantitative RT-PCR that miR-593-5p down-regulates the expression of PLK1 protein. Finally, PLK1 overexpression was shown to disinhibit NSCLC cell proliferation. Taken together, this evidence suggests that miR-593-5p inhibits NSCLC cell proliferation by inhibiting PLK1 expression.     

miR-197-3p调控DMBT1抑制甲状腺癌细胞系增殖、迁移和侵袭

目的探讨miR-197-3p是否通过靶向调控恶性脑瘤缺失1基因(DMBT1)影响甲状腺癌细胞增殖、迁移和侵袭。方法RT-qPCR检测健康人甲状腺细胞Nthy-ori 3-1和甲状腺癌细胞SW579、CGTHW-1中miR-197-3p表达;MTT法检测SW579细胞增殖;Transwell小室法检测SW579细胞迁移和侵袭;双荧光素酶报告基因实验验证miR-197-3p是否靶向DMBT1;Western blot检测细胞DMBT1、cyclinD1、p21、MMP-2和E-cadherin蛋白表达。结果与Nthy-ori 3-1细胞比较,SW579和CGTHW-1细胞中miR-197-3p相对表达量升高(P<0.05);抑制miR-197-3p表达后,SW579细胞的增殖、迁移和侵袭能力明显受到抑制,细胞中cyclinD1蛋白和MMP-2蛋白表达降低而p21蛋白和E-cadherin蛋白表达升高;SW579细胞中miR-197-3p靶向负调控DMBT1的表达;过表达DMBT1明显抑制SW579细胞增殖、迁移和侵袭,而抑制DMBT1则能逆转miR-197-3p对SW579细胞增殖、迁移和侵袭的影响。结论miR-197-3p通过靶向调控DMBT1的表达,抑制甲状腺癌细胞增殖、迁移和侵袭。     

MiR-152 regulates metastases of non-small cell lung cancer cells by targeting neuropilin-1

MicroRNAs (miRNAs) are a class of small non-coding RNAs that have been suggested to play critical roles in tumorigenesis. Recently, miR-152 was reported to be dysregulated in some human cancers. However, the function and mechanism of miR-152 in non-small cell lung cancer (NSCLC) is still unclear. In the present study, our findings showed that the expression of miR-152 was significantly down-regulated and neuropilin-1 was up-regulated in the NSCLC specimens. Moreover, the levels of miR-152 and neuropilin-1 were inversely correlated. Bioinformatics analyses and luciferase reporter assay showed that miR-152 targeted the 3’-UTR of neuropilin-1 mRNA to inhibit its translation. Furthermore, overexpression of miR-152 inhibited neuropilin-1 mediated cell invasiveness, while down-regulated expression of miR-152 increased neuropilin-1 mediated cell invasiveness in NSCLC cells. Together, these findings indicated that miR-152 suppression in NSCLC cells might promote neuropilin-1 mediated cancer metastasis and suggested a new therapeutic application of miR-152 in the treatment of NSCLC.